A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

• Status: RECRUITING
• Trial end date: 2029-01-19

Summary

The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.

• Phase: PHASE3

Details

• Lead Sponsor: Celgene
• Treatments: abiraterone; Docetaxel; enzalutamide; Prednisolone